drugset / Trial / NCT06196840
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
Timeline
- Start
- 2024-01-24
- Primary completion
- 2025-06-24
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | — | Intravitreal |
| Subject | LX102 | Gene therapy (AAV / viral vector) | — | Other |